SCHEMBL20620189

SCHEMBL20620189

Cc1c(Br)sc2c1CCN(C(=O)c1ccc(N)cc1)c1ccccc1-2

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AVPR2 P30518 2/20 0.46
AVPR1A P37288 2/20 0.46
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 2/20 0.44
NPC1 O15118 2/20 0.44
KMT2A Q03164 1/20 0.44
PDCD1 Q15116 5/20 0.39
CD274 Q9NZQ7 5/20 0.39
KCNN4 O15554 1/20 0.39
KCNA3 P22001 1/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.38
USP2 O75604 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.36
NOTUM Q6P988 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20619540 0.86 L3MBTL1 (0.42) RAB9ASMN1; SMN2HPGDNPC1KMT2A
SCHEMBL20619666 0.81 AVPR2 (0.48) AVPR2AVPR1ARAB9ASMN1; SMN2HPGD
SCHEMBL19078674 0.78 RAB9A (0.51) AVPR2AVPR1ARAB9ASMN1; SMN2HPGD
SCHEMBL20619653 0.77 RAB9A (0.43) AVPR2AVPR1ARAB9ASMN1; SMN2HPGD
SCHEMBL20620133 0.77 RAB9A (0.41) AVPR2AVPR1ARAB9ASMN1; SMN2HPGD
SCHEMBL20619512 0.77 RAB9A (0.41) AVPR2AVPR1ARAB9ASMN1; SMN2HPGD
SCHEMBL8820844 0.74 AVPR2 (0.54) AVPR2AVPR1ARAB9ASMN1; SMN2HPGD
SCHEMBL7351134 0.74 AVPR2 (0.59) AVPR2AVPR1ARAB9ASMN1; SMN2HPGD
SCHEMBL8556725 0.74 AVPR2 (0.48) AVPR2AVPR1ARAB9ASMN1; SMN2HPGD
SCHEMBL8559469 0.73 AVPR2 (0.65) AVPR2AVPR1ARAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091501-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-08-17 US disclosed
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-01-03 US disclosed
WO-2019006295-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091501-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 AVPR2 1011/4885AVPR1A 1410/4885RAB9A 575/4885
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 AVPR2 1011/4885AVPR1A 1410/4885RAB9A 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.